Related Experiment Video
Updated: Aug 16, 2026
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
All-Trans Retinoic Acid in Rodent Models of Autoimmune Diabetes: Clinical Potential of Targeted Drug Delivery
Benjamin Green1, Dominick L Auci1
1Therapyx, Inc, Buffalo, New York, United States.
Abstract:
Type 1 diabetes (T1D) is a chronic disease characterized by the relentless autoimmune destruction of insulin-producing pancreatic beta cells (β cells). Approximately 9.5 million people worldwide live with T1D; 1.9 million are under 20 years old. There is no cure and there are few effective treatments, making novel therapies desperately needed. All-trans retinoic acid (ATRA) has demonstrated promise in preventing and even ameliorating T1D, particularly in various rodent T1D models. The benefits are thought to be mediated by influences on T cells, particularly regulatory (Treg) and autoreactive effector T cells. Intriguingly, ATRA may also directly contribute to the differentiation and maintenance of pancreatic β cells. This mini review will focus on experiences with ATRA in rodent models of T1D, including measures of efficacy, Treg expansion, reduction of autoreactive effector T-cell activity and oxidative stress, and, perhaps most promisingly, preservation and stimulation of pancreatic β cells. We will then discuss the clinical potential of ATRA in T1D, including targeted drug delivery strategies to deliver ATRA locally to the relevant immune microenvironment, limiting its systemic exposure, reducing toxic side effects, and enhancing efficacy.
Insights
All-trans retinoic acid (ATRA) shows promise for type 1 diabetes (T1D) by modulating immune cells and potentially preserving pancreatic beta cells. Further research explores ATRA
Area of Science:
- Immunology
- Endocrinology
- Cell Biology
Background:
- Type 1 diabetes (T1D) involves autoimmune destruction of pancreatic beta cells, affecting millions globally.
- Current treatments for T1D are limited, necessitating novel therapeutic strategies.
- All-trans retinoic acid (ATRA) has emerged as a potential therapeutic agent for T1D.
Purpose of the Study:
- To review the efficacy of ATRA in rodent models of T1D.
- To explore ATRA's mechanisms, including immune cell modulation and direct effects on beta cells.
- To discuss the clinical potential and delivery strategies for ATRA in T1D treatment.
Main Methods:
- Review of studies using ATRA in rodent models of T1D.
- Analysis of ATRA's impact on T cells (Treg and effector cells).
- Assessment of ATRA's effects on pancreatic beta cell function and survival.
Main Results:
- ATRA demonstrates efficacy in preventing and ameliorating T1D in rodent models.
- ATRA influences T cell populations, promoting regulatory T cells and reducing autoreactive cells.
- ATRA shows potential for preserving and stimulating pancreatic beta cells, reducing oxidative stress.
Conclusions:
- ATRA holds significant promise as a novel therapy for T1D.
- Targeted delivery of ATRA could enhance efficacy and reduce side effects in clinical applications.
- Further investigation into ATRA's direct effects on beta cells is warranted.
